Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

被引：0
|
作者：
Venturella, Fabio [1 ]
Cancellieri, Giulia [1 ]
Giammanco, Marco [2 ]
Almerico, Anna Maria [1 ]
Aleo, Igor Daniele
Liga, Anastasia Valentina [1 ]
Mortillaro, Francesca [1 ]
Mistretta, Irene [1 ]
机构：
[1] Univ Palermo, Biol Chem & Pharmaceut Sci & Technol Dept, Palermo, Italy
[2] Univ Palermo, Surg Oncol & Stomatol Disciplines Dept, Palermo, Italy
来源：
JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE | 2023年 / 96卷 / 01期
关键词：
cancer; lung; immuno-oncology; Nivolumab; SAFETY;
D O I：
10.4081/jbr.2023.11027
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer ( NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
    Garon, Edward B.
    Rizvi, Naiyer A.
    Hui, Rina
    Leighl, Natasha
    Balmanoukian, Ani S.
    Eder, Joseph Paul
    Patnaik, Amita
    Aggarwal, Charu
    Gubens, Matthew
    Horn, Leora
    Carcereny, Enric
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Jong-Seok
    Hellmann, Matthew D.
    Hamid, Omid
    Goldman, Jonathan W.
    Soria, Jean-Charles
    Dolled-Filhart, Marisa
    Rutledge, Ruth Z.
    Zhang, Jin
    Lunceford, Jared K.
    Rangwala, Reshma
    Lubiniecki, Gregory M.
    Roach, Charlotte
    Emancipator, Kenneth
    Gandhi, Leena
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) : 2018 - 2028
  • [42] Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer
    Takatoshi Enomoto
    Akihiro Tamiya
    Kinnosuke Matsumoto
    Yuichi Adachi
    Koji Azuma
    Yuji Inagaki
    Shunichi Kouno
    Yoshihiko Taniguchi
    Nobuhiko Saijo
    Kyoichi Okishio
    Shinji Atagi
    Clinical and Translational Oncology, 2021, 23 : 582 - 590
  • [43] Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China
    Chai, Qingqing
    Shen, Yunjie
    Du, Jiangyang
    Zhu, Jun
    Wu, Bin
    IMMUNOTHERAPY, 2020, 12 (04) : 245 - 254
  • [44] Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer
    Umehara, Kengo
    Yama, Kaori
    Goto, Keisuke
    Wakamoto, Azusa
    Hatsuyama, Tae
    Honjo, Osamu
    Saikai, Toyohiro
    Fujita, Akihisa
    Sato, Hideki
    CANCER CONTROL, 2021, 28
  • [45] A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
    Liu, C.
    Gong, J.
    Yu, H.
    Liu, Q.
    Wang, S.
    Wang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S638 - S638
  • [46] CD47 polymorphism for predicting nivolumab benefit in patients with advanced non-small-cell lung cancer
    Ogimoto, Tatsuya
    Ozasa, Hiroaki
    Yoshida, Hironori
    Nomizo, Takashi
    Funazo, Tomoko
    Yoshida, Hiroshi
    Hashimoto, Kentaro
    Hosoya, Kazutaka
    Yamazoe, Masatoshi
    Ajimizu, Hitomi
    Tsuji, Takahiro
    Sakamori, Yuichi
    Kuninaga, Kiyomitsu
    Morita, Satoshi
    Hirai, Toyohiro
    ONCOLOGY LETTERS, 2023, 26 (02)
  • [47] Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer
    Shibata, Yuji
    Murakami, Shuji
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (06) : 653 - 659
  • [48] A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
    Liu, Chang
    Gong, Jing
    Yu, Hui
    Liu, Quan
    Wang, Shengping
    Wang, Jialei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] PEMETREXED MAINTENANCE TREATMENT IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Megaiz, Ahlem
    Bousahba, Abdelkader
    Rabah, Aicha
    Zemmour, Amel
    Ahed-Messaoud, Malika
    Ghazli, Soumia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S588 - S589
  • [50] Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Rizvi, Naiyer A.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Gettinger, Scott
    Chow, Laura Q.
    Gerber, David E.
    Laurie, Scott A.
    Goldman, Jonathan W.
    Shepherd, Frances A.
    Chen, Allen C.
    Shen, Yun
    Nathan, Faith E.
    Harbison, Christopher T.
    Antonia, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2969 - +
12345